

May 1, 2008

**APA DSM-V Work Group Member**

**Name, Degree:** Bryan H. King, M.D.

**Role(s) in Work Group:** Member, Neurodevelopmental Disorders Work Group

**Institutional Affiliation(s):** University of Washington, Seattle Children’s Hospital

**City, State:** Seattle, WA

**Biographical Sketch:**

Dr. King is Professor and Vice Chair of Psychiatry and Behavioral Sciences and Director of Child and Adolescent Psychiatry at the University of Washington and Seattle Children’s Hospital. He joined the University from Dartmouth Medical School where he held a similar position as well as serving as the Medical Director for New Hampshire’s Division of Developmental Services.

Dr. King completed his medical training at the Medical College of Wisconsin, and subsequently did his medical internship and psychiatric training at the UCLA Medical Center and Neuropsychiatric Institute. He obtained his clinical and research training in Child and Adolescent Psychiatry at UCLA and at the Merck Neuroscience Research Center in England with sponsorship of the National Institutes of Health.

Dr. King’s clinical and research interests have been focused on psychiatric aspects of developmental disorders, repetitive movements, and upon the pathogenesis and treatment of severe behavioral disturbance in particular. He currently chairs a multi-site clinical trial by the National Institutes of Health funded STAART (Studies to advance autism research and treatment) Centers examining the potential role for an antidepressant medication in the treatment of children with autism who have significant problems with repetitive behaviors. He is also Director of the NIH funded UW Autism Center of Excellence. Dr. King is a co-author on the practice parameters for children and adults with developmental disorders and mental illnesses by the American Academy of Child and Adolescent Psychiatry. He has written extensively in the medical literature relating to this field, and has received lifetime achievement awards from the American Academy of Child and Adolescent Psychiatry, and from the American Psychiatric Association, for his work in the field of Developmental Disabilities. He has been recognized for his clinical care in several venues including having once been selected as the Outstanding Physician by the nursing staff of the UCLA Neuropsychiatric Institute and the Family Choice Award at Seattle Children’s Hospital.

**UNCOMPENSATED AFFILIATIONS WITH NON-PROFIT OR ADVOCACY ORGANIZATIONS** THAT MAY HAVE A DIRECT OR INDIRECT INTEREST IN PSYCHIATRIC DIAGNOSIS, TREATMENT, OR THE DSM-V : **CALENDAR YEARS 2005, 2006, 2007, AND FOR 2008**, ACTIVITIES TO DATE AND COMMITMENTS FOR REMAINDER OF YEAR.

<b>Non-Profit and Advocacy Organizations</b>	<b>Year(s)</b>	<b>Role</b>
Cure Autism Now	2005-2007	Clinical Trials Taskforce Member
American Board of Psychiatry and Neurology	2005-2008	Examiner

The two tables below represent Dr. King's disclosure of significant interests and affiliations for: (1) The full calendar years of 2005, 2006, and 2007; and (2) for 2008, interests and affiliations to date and commitments for remainder of the year.

Dr. King has agreed that, from the time of approval through the publication of DSM-V, projected in 2012, (his/her) aggregate annual income derived from industry sources (excluding unrestricted research grants) will not exceed \$10,000 in any calendar year.

<p><b>KEY NUMBER:</b></p> <p>1. Consultation Fees (include scientific advisory boards)</p> <p>2. Full- or Part-time Employee</p> <p>3. Industry-related Grant-Research Support received or pending</p> <p>4. Honoraria (includes Speakers' Bureau)</p> <p>5. Stock or other financial options</p>	<p>6. Expert testimony</p> <p>7. Royalties (including right to share of revenue or profit from pharmaceutical, device or other development or product)</p> <p>8. Patents received or pending</p> <p>9. Officer, director/trustee, executive (specify)</p> <p>10. Other (specify)</p>
---	--

**DISCLOSURE OF SIGNIFICANT INTERESTS FOR 2005, 2006, AND 2007**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
Medpoint Communication (Supported by Janssen Pharmaceutica)	2005	4
Maher, Guiley and Maher	2005	5
Biomarin (SAB)	2007	1
Neuropharm/ Autism Speaks Collaboration	2007	3
Nastech	2007	1 (unpaid)
Seaside Therapeutics	2007	1 (unpaid)
Danden Health Media	2005	4
Humana Press	2005	4
Wolters Kluwer Health	2005	4
Warwick Media	2005	4
Adventist Health System	2005	6

UPDATED 4.25.08

**DISCLOSURE OF SIGNIFICANT INTERESTS TO DATE FOR 2008 AND COMMITMENTS FOR REMAINDER OF YEAR**

<b>Commercial or Other Organization</b>	<b>Year(s)</b>	<b>Key #(s)</b>
Neuropharm/Autism Speaks Collaboration	2008	3
Roche	2008	1 (unpaid)
Seaside Therapeutics	2008	3 (pending)